Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.36 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26113891 | 0.88 | SIRT6 (0.39) | PDE4BPDE4DPDE4APDE4CSIRT6 | |
| SCHEMBL31352847 | 0.86 | PDE4B (0.46) | PDE4BGPR119IKBKETBK1PDE4D | |
| SCHEMBL30590963 | 0.86 | PDE4B (0.46) | PDE4BGPR119IKBKETBK1PDE4D | |
| SCHEMBL21612833 | 0.83 | PDE4D (0.47) | PDE4BGPR119PDE4DPDE4APDE4C | |
| SCHEMBL21612772 | 0.82 | PDE4B (0.44) | PDE4BGPR119PDE4DPDE4APDE4C | |
| SCHEMBL21612831 | 0.82 | GPR119 (0.52) | PDE4BGPR119PDE4DPDE4APDE4C | |
| SCHEMBL21612843 | 0.81 | PDE4B (0.45) | PDE4BGPR119PDE4DPDE4APDE4C | |
| SCHEMBL23355348 | 0.79 | PDE4B (0.43) | PDE4BGPR119PDE4DPDE4APDE4C | |
| SCHEMBL30203345 | 0.79 | PDE4B (0.43) | PDE4BGPR119PDE4DPDE4APDE4C | |
| SCHEMBL28983495 | 0.79 | GPR119 (0.49) | PDE4BGPR119PDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325471-A | EGFR inhibitors | 缆图药品公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PDE4B 3591/4885GPR119 1916/4885IKBKE 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.